543828
Sudarshan Pharma financials
- Market cap
- ₹985 Cr
- Sector
- Chemicals
What Sudarshan Pharma does
Sudarshan Pharma Industries manufactures and sources specialty chemicals, API intermediates and active pharmaceutical ingredients, which it upward-integrates into finished pharmaceutical formulations and branded generic drugs. It operates manufacturing units at Palghar (Maharashtra), Jejuri and Hyderabad (Telangana), the last GMP- and ISO 9001:2015-certified for API/intermediate manufacturing. The group also holds several subsidiaries covering specialty chemical trading (dyestuffs, pigments, solvents), oncology API intermediates, and medical-device consumables (sutures, meshes, catheters), and exports its products to over 10 countries.
Segments
- Chemical raw materials for pharmaceuticals
- Intermediates for API
- API manufacturing and import
- Finished formulation and F&O R&D
- Branded generics
- Manufacturing facilities
- 3 (Palghar & Jejuri, Maharashtra; Hyderabad, Telangana)
- Export presence
- 10+ countries
- Pharma product portfolio
- 96 products (56 registered under "R" trademark)
- Subsidiaries
- 7 (India, Singapore, Dubai)
- Palghar plant - approved products
- 50 (domestic & international)
- Palghar oral-liquid production capacity
- 2,000 litres/shift, scalable to 6,000 litres across two shifts
Quarterly results
Q1 FY27: revenue up 16.4%, net profit up 61.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 124 | 116 | 162 | 142 | 167 +35% | 158 +37% | 200 +24% | 166 +16% |
| EBITDA | 12 | 8 | 15 | 10 | 10 −23% | 11 +35% | 18 +20% | 16 +58% |
| Net profit | 5 | 3 | 7 | 4 | 4 −19% | 4 +56% | 10 +36% | 6 +62% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +21.4% 1Y
1Y: ₹32.12 on 10 Sept 2025 → ₹39. High ₹42.31 (21 Jul 2026), low ₹19.23 (27 Jan 2026).
Financials, as filed
Revenue grew 32.8% a year over 1 year, FY25 to FY26. Operating margin held at 7.3%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹502 Cr | ₹668 Cr |
| Operating profit | ₹38 Cr | ₹49 Cr |
| Operating margin | 7.5% | 7.3% |
| Interest | ₹16 Cr | ₹25 Cr |
| Depreciation | ₹3 Cr | ₹3 Cr |
| Net profit | ₹14 Cr | ₹22 Cr |
| Net margin | 2.8% | 3.3% |
| Cash from operations | ₹35 Cr | ₹-3 Cr |
| Free cash flow | ₹34 Cr | ₹-52 Cr |
| ROCE | 15.0% | 15.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹10 Cr | ₹10 Cr | ₹24 Cr | ₹24 Cr | ₹24 Cr | ₹24 Cr |
| Reserves | ₹13 Cr | ₹20 Cr | ₹77 Cr | ₹88 Cr | ₹116 Cr | ₹129 Cr |
| Borrowings | ₹30 Cr | ₹31 Cr | ₹34 Cr | ₹107 Cr | ₹219 Cr | ₹282 Cr |
| Other liabilities | ₹47 Cr | ₹77 Cr | ₹97 Cr | ₹66 Cr | ₹148 Cr | ₹159 Cr |
| Total liabilities | ₹99 Cr | ₹138 Cr | ₹232 Cr | ₹285 Cr | ₹507 Cr | ₹594 Cr |
| Fixed assets | ₹6 Cr | ₹6 Cr | ₹20 Cr | ₹21 Cr | ₹53 Cr | ₹94 Cr |
| Capital work in progress | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹2 Cr | ₹28 Cr | ₹3 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹12 Cr | ₹17 Cr | ₹2 Cr | ₹8 Cr |
| Other assets | ₹93 Cr | ₹130 Cr | ₹200 Cr | ₹245 Cr | ₹424 Cr | ₹489 Cr |
| Total assets | ₹99 Cr | ₹138 Cr | ₹232 Cr | ₹285 Cr | ₹507 Cr | ₹594 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Aug 2026
Since Sep 2025, promoters added +1.54 pp while FIIs trimmed −0.91 pp. The shareholder count shrank 12% to 1,217.
- Promoters
- 58.9%
- FIIs
- 19.9%
- Government
- 0.1%
- Public
- 21.1%
Since Sep 2025
- Promoters +1.54 pp
- FIIs −0.91 pp
- Public −0.61 pp
How it drifted, 11 quarters
Over this window the public fell from 39.0% to 21.1% — −17.9 pp.
Ownership split by quarter, oldest first. Mar '23: Promoters 57.4%, FIIs 3.6%, Public 39.0%.Sep '23: Promoters 57.4%, FIIs 1.4%, Public 41.2%.Mar '24: Promoters 57.4%, FIIs 1.4%, Public 41.2%.Sep '24: Promoters 57.4%, FIIs 13.1%, Public 29.5%.Mar '25: Promoters 57.4%, FIIs 18.4%, Public 24.2%.Jun '25: Promoters 57.4%, FIIs 19.5%, Government 0.1%, Public 23.1%.Sep '25: Promoters 57.4%, FIIs 20.8%, Government 0.1%, Public 21.8%.Dec '25: Promoters 57.4%, FIIs 19.8%, Government 0.1%, Public 22.8%.Mar '26: Promoters 57.4%, FIIs 19.9%, Government 0.1%, Public 22.6%.Jun '26: Promoters 58.9%, FIIs 19.4%, Government 0.1%, Public 21.6%.Aug '26: Promoters 58.9%, FIIs 19.9%, Government 0.1%, Public 21.1%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- North Star Opportunities Fund Vcc-Bull Value Incorporated Vcc Sub-Fund FPI fund newly disclosed 1.65% held
- Saumik Ketankumar Doshi +1.00 pp 2.62% held
The same filing shows 2 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Aug 2026 filing
Every holder of Sudarshan Pharma above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Sachin Vasantrai Mehta | 28.32% | unchanged |
| Hemal Vasantrai Mehta | 27.45% | unchanged |
| Multitude Growth Funds Limited FPI fund | 4.23% | −0.45 pp |
| Century India Opportunity Fund Pc FPI fund | 3.24% | unchanged |
| Saumik Ketankumar Doshi | 2.62% | +1.00 pp |
| Eminence Global Fund Pcc- Eubilia Capital Partners FPI fund | 1.95% | unchanged |
| Ebisu Global Opportunities Fund Limited FPI fund | 1.92% | unchanged |
| Coeus Global Opportunities Fund FPI fund | 1.68% | unchanged |
| North Star Opportunities Fund Vcc-Bull Value Incorporated Vcc Sub-Fund FPI fund | 1.65% | newly disclosed |
| Bridge India Fund FPI fund | 1.59% | unchanged |
| Nexpact Limited FPI fund | 1.50% | −0.33 pp |
| Devangi Hemal Mehta | 0.92% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
AttractiveTo justify its price of ₹39, this stock must grow earnings at 30% every year for 7 years. Our analysis caps realistic growth at ~41%. At that growth it is worth ₹67 — upside of 71%.
- Growth the price implies
- 29.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 40.9% a year
- net profit, FY25–FY26 · EPS 40.9%
- The gap
- -0.1 pp
- 71% downside if it only repeats history
Learn to analyse Sudarshan Pharma
Guides on how to read this kind of business and the numbers that matter.